BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857-861. [PMID: 14999707 DOI: 10.1002/hep.20110] [Cited by in Crossref: 354] [Cited by in F6Publishing: 323] [Article Influence: 19.7] [Reference Citation Analysis]
Number Citing Articles
1 Chevaliez S, Pawlotsky J. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Annals of Hepatology 2009;8:7-12. [DOI: 10.1016/s1665-2681(19)31804-6] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
2 Verma S, Thuluvath PJ. Correlation Between Hepatitis B Virus DNA Levels and Liver Histology: Is the Controversy Because of Paucity of Data? Journal of Clinical Gastroenterology 2007;41:339-42. [DOI: 10.1097/mcg.0b013e31803238c6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain: . European Journal of Gastroenterology & Hepatology 2008;20:320-6. [DOI: 10.1097/meg.0b013e3282f340c8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Liaw Y. Management of chronic hepatitis B: an evolving issue. Liver International 2006;26:1-2. [DOI: 10.1111/j.1478-3231.2006.01369.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat. 2006;13:250-255. [PMID: 16611191 DOI: 10.1111/j.1365-2893.2005.00687.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
6 Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Miyakawa Y, Kumada H. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007;79:1472-7. [PMID: 17705186 DOI: 10.1002/jmv.20994] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
7 Wu I, Chow N, Cheng P, Liu W, Young K, Chang W, Chen C, Tseng K, Chang T. Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B. J Med Virol 2007;79:663-9. [DOI: 10.1002/jmv.20822] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
8 Mu D, Yuan FC, Chen Y, Jiang XY, Yan L, Jiang LY, Gong JP, Zhang DZ, Ren H, Liao Y. Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy. Sci Rep. 2017;7:5937. [PMID: 28725013 DOI: 10.1038/s41598-017-05242-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
9 Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 2009;24:49-54. [PMID: 19196395 DOI: 10.1111/j.1440-1746.2008.05570.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
10 Jang MK, Choi DR, Lee JY, Moon HK, Lee JH, Kim SM, Kim KH, Park JY, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK, Yoo JY. Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission. Journal of Infection 2005;51:314-7. [DOI: 10.1016/j.jinf.2005.01.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Tan CX, Chan SM, Lee LY, Ong C, Phua KB, Aw MM, Saw S, Lee GH, Wong F, Thoon KC. Serologic Responses After Hepatitis B Vaccination in Preterm Infants Born to Hepatitis B Surface Antigen-Positive Mothers: Singapore Experience. Pediatr Infect Dis J 2017;36:e208-10. [PMID: 28198787 DOI: 10.1097/INF.0000000000001578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Okita R, Takahashi M, Narahara H, Sanada Y, Okada M, Kawakami Y, Chayama K, Okita K. Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy. Clin J Gastroenterol 2009;2:214-7. [DOI: 10.1007/s12328-009-0063-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
13 Sherman M. Predicting survival in hepatitis B. Gut. 2005;54:1521-1523. [PMID: 16227355 DOI: 10.1136/gut.2005.071332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
14 Flores-calderón J, Gómez-díaz RA, Rodríguez-gómez G, Morán-villota S. Frequency of increased aminotransferases levels and associated metabolic abnormalities in obese and overweight children of an elementary school in Mexico City. Annals of Hepatology 2005;4:279-83. [DOI: 10.1016/s1665-2681(19)32053-8] [Cited by in Crossref: 18] [Article Influence: 1.1] [Reference Citation Analysis]
15 Tsai FC, Hsieh SC, Chen DS, Sheu JC, Chen CH. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci. 2006;51:1627-1632. [PMID: 16927141 DOI: 10.1007/s10620-006-9074-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
16 Mast EE, Ward JW. Hepatitis B vaccines. Vaccines. Elsevier; 2008. pp. 205-41. [DOI: 10.1016/b978-1-4160-3611-1.50017-9] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
17 Pereira SA, Caixas U, Branco T, Germano I, Lampreia F, Papoila AL, Monteiro EC. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol 2008;66:551-5. [PMID: 18662298 DOI: 10.1111/j.1365-2125.2008.03238.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
18 Mondal G, Saroha A, Bose PP, Chatterjee BP. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J 2016;33:209-18. [PMID: 27034286 DOI: 10.1007/s10719-016-9658-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
19 Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005;51:328-335. [PMID: 15590748 DOI: 10.1373/clinchem.2004.041764] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
20 Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307-313. [PMID: 17256746 DOI: 10.1002/hep.21534] [Cited by in Crossref: 243] [Cited by in F6Publishing: 220] [Article Influence: 16.2] [Reference Citation Analysis]
21 Park S, Park ES, Koo JE, Park YK, Lee AR, Dezhbord M, Cho ES, Ahn SH, Kim DH, Lee JH, Lee HC, Kim KH. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver Int 2020;40:1564-77. [PMID: 32216026 DOI: 10.1111/liv.14446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Winther TN, Heiberg IL, Bang-Berthelsen CH, Pociot F, Hogh B. Hepatitis B surface antigen quantity positively correlates with plasma levels of microRNAs differentially expressed in immunological phases of chronic hepatitis B in children. PLoS One 2013;8:e80384. [PMID: 24244683 DOI: 10.1371/journal.pone.0080384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
23 Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007; 13(4): 525-531 [PMID: 17278217 DOI: 10.3748/wjg.v13.i4.525] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 88] [Article Influence: 6.5] [Reference Citation Analysis]
24 Ma H, Wei L, Guo F, Zhu S, Sun Y, Wang H. Clinical features and survival in Chinese patients with hepatitis B e antigen-negative hepatitis B virus-related cirrhosis. Journal of Gastroenterology and Hepatology 2008;23:1250-8. [DOI: 10.1111/j.1440-1746.2008.05499.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
25 Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol. 2007;41:403-411. [PMID: 17413611 DOI: 10.1097/01.mcg.0000248018.08515.f9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 4.3] [Reference Citation Analysis]
26 Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40:1262-1269. [PMID: 25312649 DOI: 10.1111/apt.12990] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
27 Garbuglia AR, Angeletti C, Lauria FN, Zaccaro P, Cocca AM, Pisciotta M, Solmone M, Capobianchi MR. Comparison of Versant HBV DNA 3.0 and COBAS AmpliPrep-COBAS TaqMan assays for hepatitis B DNA quantitation: Possible clinical implications. J Virol Methods 2007;146:274-80. [PMID: 17707918 DOI: 10.1016/j.jviromet.2007.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang X, Xie G, Zhao A, Zheng X, Huang F, Wang Y, Yao C, Jia W, Liu P. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. J Proteome Res 2016;15:1126-34. [PMID: 25964117 DOI: 10.1021/acs.jproteome.5b00217] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
29 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
30 Wiegand J, Meya S, Schlaphoff V, Manns MP, Mössner J, Wedemeyer H, Tillmann HL. HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat 2010;17:631-9. [PMID: 19889141 DOI: 10.1111/j.1365-2893.2009.01220.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
31 Yuen M, Lai C. Telbivudine for chronic hepatitis B: the GLOBE trial. Future Virology 2008;3:317-23. [DOI: 10.2217/17460794.3.4.317] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Kim SU, Ahn SH, Park JY, Kang W, Kim do Y, Park YN, Chon CY, Han KH. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol. 2009;43:267-271. [PMID: 18987556 DOI: 10.1097/mcg.0b013e31816f212e] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
33 Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818. [PMID: 24696492 DOI: 10.1128/jvi.00635-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
34 Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, Cheong JW, Lee ST, Min YH. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin’s lymphoma. Yonsei Med J. 2007;48:78-89. [PMID: 17326249 DOI: 10.3349/ymj.2007.48.1.78] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
35 Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol. 2009;50:990-998. [PMID: 19303657 DOI: 10.1016/j.jhep.2008.12.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
36 Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Arase Y, Ikeda K, Kumada H. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007;42:368-74. [PMID: 17530361 DOI: 10.1007/s00535-007-2008-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
37 Karahasanoğlu FB, Asan A, Sacar S, Turgut H. Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections. Balkan Med J. 2013;30:375-381. [PMID: 25207144 DOI: 10.5152/balkanmedj.2013.7547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
38 Soriano V, Sheldon J, Ramos B, Núñez M. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. AIDS 2006;20:451-3. [PMID: 16439880 DOI: 10.1097/01.aids.0000200538.25103.3a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
39 Cooksley WG. Peginterferon-alpha 2a for the treatment of hepatitis B infection. Expert Opin Pharmacother 2005;6:1373-80. [PMID: 16013986 DOI: 10.1517/14656566.6.8.1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Buti M. Tratamiento de la hepatitis crónica B HBeAg negativo. Gastroenterología y Hepatología 2006;29:50-3. [DOI: 10.1157/13097578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Sherman M. Personal view: the management of chronic hepatitis B infection. Aliment Pharmacol Ther 2006;23:857-69. [DOI: 10.1111/j.1365-2036.2006.02840.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
42 Perrillo R. Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner. J Am Acad Nurse Pract 2006;18:203-15. [PMID: 16681707 DOI: 10.1111/j.1745-7599.2006.00124.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141-1150. [PMID: 19338056 DOI: 10.1002/hep.22760] [Cited by in Crossref: 336] [Cited by in F6Publishing: 308] [Article Influence: 25.8] [Reference Citation Analysis]
44 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015; 7(8): 1097-1104 [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
45 Ha NB, Ha NB, Garcia RT, Trinh HN, Chaung KT, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011;56:2423-31. [PMID: 21327918 DOI: 10.1007/s10620-011-1610-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
46 Raoufy MR, Vahdani P, Alavian SM, Fekri S, Eftekhari P, Gharibzadeh S. A Novel Method for Diagnosing Cirrhosis in Patients with Chronic Hepatitis B: Artificial Neural Network Approach. J Med Syst 2011;35:121-6. [DOI: 10.1007/s10916-009-9348-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
47 Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45:1172-1178. [PMID: 17464992 DOI: 10.1002/hep.21629] [Cited by in Crossref: 100] [Cited by in F6Publishing: 83] [Article Influence: 6.7] [Reference Citation Analysis]
48 Alter HJ. Management of hepatitis virus infections. Haemophilia 2008;14 Suppl 3:26-32. [PMID: 18510518 DOI: 10.1111/j.1365-2516.2008.01739.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009;5:868-76. [PMID: 19603122 DOI: 10.1039/b820224a] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 12.2] [Reference Citation Analysis]
50 Berraondo P, Ochoa L, Crettaz J, Rotellar F, Vales A, Martínez-Ansó E, Zaratiegui M, Ruiz J, González-Aseguinolaza G, Prieto J. IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Mol Ther. 2005;12:68-76. [PMID: 15963922 DOI: 10.1016/j.ymthe.2005.02.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
51 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ;  Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686. [PMID: 16530509 DOI: 10.1053/j.gastro.2005.11.016] [Cited by in Crossref: 1074] [Cited by in F6Publishing: 980] [Article Influence: 67.1] [Reference Citation Analysis]
52 Chen Y, Li X, Ye B, Yang X, Wu W, Chen B, Pan X, Cao H, Li L. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res. 2011;91:23-31. [PMID: 21549152 DOI: 10.1016/j.antiviral.2011.04.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
53 Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 2014;7:259-68. [DOI: 10.1586/eri.09.6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
54 Liu C, Lai M, Chao Y, Liao L, Yang S, Hsiao T, Hsieh T, Lin C, Hu J, Chen C, Chen P, Kao J, Chen D. Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study. Hepatology 2006;43:742-9. [DOI: 10.1002/hep.21100] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
55 Zarski J, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-carrie N, Barange K, Canva V, Doffoel M, Cales P. Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. Journal of Hepatology 2006;45:355-60. [DOI: 10.1016/j.jhep.2006.03.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
56 Rodríguez-frias F, Jardi R. Virología molecular del virus de la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 2008;26:2-10. [DOI: 10.1016/s0213-005x(08)76514-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
57 Sarin S, Kumar M, Tyagi P. HBV carrier or chronic HBV infection: Need for change in terminology. J Gastroenterol Hepatol 2004;19:S103-7. [DOI: 10.1111/j.1440-1746.2004.03654.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Ceccarelli L, Salpini R, Sarmati L, Svicher V, Bertoli A, Sordillo P, Ricciardi A, Perno CF, Andreoni M, Sarrecchia C. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65:180-183. [PMID: 22138369 DOI: 10.1016/j.jinf.2011.11.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
59 Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006;28:184-203. [PMID: 16678641 DOI: 10.1016/j.clinthera.2006.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
60 Papatheodoridis GV, Manesis EK, Manolakopoulos S, Archimandritis AJ. Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen–negative chronic hepatitis B virus infection. Hepatology 2007;46:606-7. [DOI: 10.1002/hep.21864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
61 Ooi M, Teoh NC. Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B-related complications? J Gastroenterol Hepatol 2012;27:1541-3. [PMID: 22994430 DOI: 10.1111/j.1440-1746.2012.07221.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
62 Thomas DL, Sulkowski MS. Detection of Liver Disease in Injection Drug Users. Journal of Addictive Diseases 2008;27:19-24. [DOI: 10.1300/j069v27n02_03] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, Tsuei DJ, Chen DS. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007;132:2340-5. [PMID: 17570209 DOI: 10.1053/j.gastro.2007.03.111] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
64 Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther. 2013;8:13-24. [PMID: 24376343 DOI: 10.2147/dddt.s41423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
65 Winther TN, Jacobsen KS, Mirza AH, Heiberg IL, Bang-Berthelsen CH, Pociot F, Hogh B. Circulating MicroRNAs in Plasma of Hepatitis B e Antigen Positive Children Reveal Liver-Specific Target Genes. Int J Hepatol 2014;2014:791045. [PMID: 25580300 DOI: 10.1155/2014/791045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
66 Byun KS, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, Yeon JE, Park JJ, Kim JS, Bak YT. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol. 2005;20:1838-1842. [PMID: 16336441 DOI: 10.1111/j.1440-1746.2005.03952.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
67 Rustgi V, Carriero D, Bachtold M, Zeldin G. Update on Chronic Hepatitis B. The Journal for Nurse Practitioners 2010;6:631-9. [DOI: 10.1016/j.nurpra.2010.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Kim YM, Jeong S, Kim J, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy. Journal of Clinical Virology 2011;51:241-5. [DOI: 10.1016/j.jcv.2011.05.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
69 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
70 Nan X, Shi S, Yu C, Zhuang H. Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection: Anti-HBc seropositivity and poor HCV prognosis. Hepatology Research 2010;40:1176-87. [DOI: 10.1111/j.1872-034x.2010.00733.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
71 Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013. World J Gastroenterol 2014; 20(40): 14581-14588 [PMID: 25356022 DOI: 10.3748/wjg.v20.i40.14581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
72 Younger HM, Bathgate AJ, Hayes PC. Review article: Nucleoside analogues for the treatment of chronic hepatitis B. Aliment Pharmacol Ther 2004;20:1211-30. [PMID: 15606384 DOI: 10.1111/j.1365-2036.2004.02211.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
73 Thimme R, Spangenberg HC, Blum HE. Hepatitis B or hepatitis C and human immunodeficiency virus infection. J Hepatol 2005;42 Suppl:S37-44. [PMID: 15777571 DOI: 10.1016/j.jhep.2005.01.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
74 Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2006;6:913-921. [PMID: 16918258 DOI: 10.1517/14712598.6.9.913] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
75 Liaw Y, Leung N, Guan R, Lau GK, Merican I, Mccaughan G, Gane E, Kao J, Omata M; for the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89. [DOI: 10.1111/j.1478-3231.2005.01134.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 14.1] [Reference Citation Analysis]
76 Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2008;2:102-110. [PMID: 19669285 DOI: 10.1007/s12072-007-9022-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
77 Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385-1391. [PMID: 16729316 DOI: 10.1002/hep.21189] [Cited by in Crossref: 239] [Cited by in F6Publishing: 214] [Article Influence: 14.9] [Reference Citation Analysis]
78 Yu S, Zhou Q, Zhao XM, Yuan M, Wang CT, Cheng XG, Zhang ZH, Li X. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study. Saudi J Gastroenterol. 2014;20:350-355. [PMID: 25434315 DOI: 10.4103/1319-3767.145320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
79 Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, Mao YM. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008;9:108-112. [PMID: 18419645 DOI: 10.1111/j.1751-2980.2008.00331.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 120] [Article Influence: 8.1] [Reference Citation Analysis]
80 Li W, Huang L, Guo H, Wei X, Liang Z. Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. J Clin Virol. 2014;61:199-203. [PMID: 25128391 DOI: 10.1016/j.jcv.2014.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
81 Molino C, Fabbian F, Cozzolino M, Longhini C. The Management of Viral Hepatitis in CKD Patients: An Unresolved Problem. Int J Artif Organs 2008;31:683-96. [DOI: 10.1177/039139880803100802] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
82 Fung SK, Wong FS, Wong DK, Hussain MT, Lok AS. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int. 2006;26:796-804. [PMID: 16911461 DOI: 10.1111/j.1478-3231.2006.01297.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
83 Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis. 2006;43:904-910. [PMID: 16941375 DOI: 10.1086/507532] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
84 van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, Lee AU. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22:1500-1505. [PMID: 17683493 DOI: 10.1111/j.1440-1746.2007.05093.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
85 Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007;9:14-22. [PMID: 17335673 DOI: 10.1007/s11894-008-0016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
86 Kuloğlu Z, Krsaçloğlu CT, Kansu A, Erden E, Girgin N. Liver Histology of Children With Chronic Hepatitis Treated With Interferon-α Alone or in Combination With Lamivudine. Journal of Pediatric Gastroenterology & Nutrition 2007;45:564-8. [DOI: 10.1097/mpg.0b013e31815604fb] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
87 Müller C. Chronic Hepatitis B and C--current treatment and future therapeutic prospects. Wien Med Wochenschr. 2006;156:391-396. [PMID: 16937041 DOI: 10.1007/s10354-006-0314-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
88 Zheng Y, Zhang S, Tan Grahn HM, Ye C, Gong Z, Zhang Q. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. Hepat Mon. 2013;13:e6496. [PMID: 23805156 DOI: 10.5812/hepatmon.6496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
89 Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL. Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther 2012;17:813-21. [PMID: 22418880 DOI: 10.3851/IMP2085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
90 Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J. 2007;83:32-39. [PMID: 17267676 DOI: 10.1136/pgmj.2006.044826] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
91 Soriano V, Nuñez M, Sheldon J, Ramos B, Garcia-Samaniego J, Martín-Carbonero L, Maida I, Gonzalez-Lahoz J. Complications in treating chronic hepatitis B in patients with HIV. Expert Opin Pharmacother 2005;6:2831-42. [PMID: 16318434 DOI: 10.1517/14656566.6.16.2831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Nousbaum JB. [A 23-year-old asymptomatic HBsAg positive woman]. Gastroenterol Clin Biol 2009;33:F56-9. [PMID: 19762187 DOI: 10.1016/j.gcb.2009.07.029] [Reference Citation Analysis]
93 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20:e3-10. [PMID: 23490387 DOI: 10.1111/jvh.12010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
94 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
95 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Shin JW, Park NH, Jung SW, Kim BC, Kwon SH, Park JS, Jeong ID, Bang SJ, Kim DH. Clinical significance of hepatitis B e antigen level easurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol 2006; 12(41): 6693-6698 [PMID: 17075986 DOI: 10.3748/wjg.v12.i41.6693] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
97 Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY;  Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011;12:38-44. [PMID: 21276207 DOI: 10.1111/j.1751-2980.2010.00476.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 155] [Article Influence: 13.5] [Reference Citation Analysis]
98 Zhang K, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis in relation to HBeAg and anti-HBe. J Med Virol 2007;79:683-93. [DOI: 10.1002/jmv.20849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
99 Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351 [PMID: 26413224 DOI: 10.4254/wjh.v7.i21.2344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
100 Tamori A, Enomoto M, Kobayashi S, Iwai S, Morikawa H, Sakaguchi H, Habu D, Shiomi S, Imanishi Y, Kawada N. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat. 2010;17:123-129. [PMID: 19674281 DOI: 10.1111/j.1365-2893.2009.01160.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
101 Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 2007;75:146-151. [PMID: 17400303 DOI: 10.1016/j.antiviral.2007.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
102 Kim HN. Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy. Curr Hepatol Rep 2020;19:345-53. [PMID: 33796434 DOI: 10.1007/s11901-020-00541-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Papatheodoridis GV. Ethics Related to Liver Biopsies and Antiviral Therapies in Chronic Viral Hepatitis. Dig Dis 2007;26:59-65. [DOI: 10.1159/000109389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
104 Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005;118:1413. [PMID: 16378788 DOI: 10.1016/j.amjmed.2005.06.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 4.6] [Reference Citation Analysis]
105 Juman Awadh A, Kyuregyan KK, Isaeva OV, Mikhailov MI. Comparative characterization of two tests for measurement of hepatitis B virus DNA in the blood serum and plasma, based on the use of two different detection methods. Bull Exp Biol Med. 2008;146:246-249. [PMID: 19145329 DOI: 10.1007/s10517-008-0260-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Zhang JC, Nie QH. New antiviral choice for chronic hepatitis B: tenofovir disoproxil fumarate. Shijie Huaren Xiaohua Zazhi 2008; 16(24): 2679-2688 [DOI: 10.11569/wcjd.v16.i24.2679] [Reference Citation Analysis]
107 Sánchez-tapias JM. Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 2008;31:120-8. [DOI: 10.1157/13116500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006;44:S90-S94. [PMID: 16352368 DOI: 10.1016/j.jhep.2005.11.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
109 Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N, Izumi N. Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B. Intervirology 2005;48:381-8. [DOI: 10.1159/000086065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
110 Hassan ZM, Wahsheh MA, Shishani KR, Pryor ER. Hepatitis needs assessment among Jordanian healthcare workers. Int Nurs Rev 2008;55:142-7. [PMID: 18477097 DOI: 10.1111/j.1466-7657.2007.00583.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Li XY, You X, Jie YS, Lin GL, Wu YK, Huang MX, Zhang M, Li ZY, Xie DY, Gao ZL, Chong YT. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy. Am J Ther 2017;24:e250-8. [PMID: 25923228 DOI: 10.1097/MJT.0000000000000262] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Park JG, Park SY. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol 2015;21:242-8. [PMID: 26523269 DOI: 10.3350/cmh.2015.21.3.242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
113 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
114 Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067. [PMID: 21188195 DOI: 10.1155/2010/182067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
115 Gish RG. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin Liver Dis. 2005;9:541-565, v. [PMID: 16207563 DOI: 10.1016/j.cld.2005.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
116 Eidi Nita M, Gaburo N, Cheinquer H, L’ltalien G, Stanislau Affonso de Araujo E, Mantilla P, Cure-bolt N, Lotufo PA. Patterns of viral load in chronic hepatitis B patients in Brazil and their association with ALT levels and HBeAg status. Annals of Hepatology 2009;8:339-45. [DOI: 10.1016/s1665-2681(19)31747-8] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
117 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
118 Fung SK, Lok AS. Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol. 2004;1:90-97. [PMID: 16265070 DOI: 10.1038/ncpgasthep0056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
119 Thibault V. Where does adefovir stand amongst newly developed antivirals: from pharmacology to virology. Future Virology 2006;1:553-65. [DOI: 10.2217/17460794.1.5.553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Hadziyannis SJ. Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state”. Hepatol Int. 2007;1:281-284. [PMID: 19669350 DOI: 10.1007/s12072-007-9004-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
121 Luo X, Yu JX, Xie L, Ma WJ, Wang LH. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients. Ann Hepatol 2017;16:888-92. [PMID: 29055925 DOI: 10.5604/01.3001.0010.5279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Inada M, Yokosuka O. Current antiviral therapies for chronic hepatitis B. Hepatol Res. 2008;38:535-542. [PMID: 18452480 DOI: 10.1111/j.1872-034X.2008.00323.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
123 Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther. 2004;2:745-760. [PMID: 15482237 DOI: 10.1586/14789072.2.5.745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
124 Wang YB, Xie W, Ou WN, Yan J, Cheng J. Therapeutic effect of adeforvir dipivoxil for HBeAg-positive patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2008; 16(23): 2666-2668 [DOI: 10.11569/wcjd.v16.i23.2666] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Loras C, Gisbert J, Saro M, Piqueras M, Sánchez-montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-bañares F, Esteve M. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). Journal of Crohn's and Colitis 2014;8:1529-38. [DOI: 10.1016/j.crohns.2014.06.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
126 Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009;81:417-24. [PMID: 19152409 DOI: 10.1002/jmv.21402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
127 Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50:36-41. [PMID: 19012989 DOI: 10.1016/j.jhep.2008.07.039] [Cited by in Crossref: 180] [Cited by in F6Publishing: 174] [Article Influence: 12.9] [Reference Citation Analysis]
128 Krastev ZA. The “return” of hepatitis B. World J Gastroenterol 2006; 12(44): 7081-7086 [PMID: 17131468 DOI: 10.3748/wjg.v12.i44.7081] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
129 Seo YS, Kim MY, Kim SU, Hyun BS, Jang JY, Lee JW, Lee JI, Suh SJ, Park SY, Park H, Jung EU, Kim BS, Kim IH, Lee TH, Um SH, Han KH, Kim SG, Paik SK, Choi JY, Jeong SW, Jin YJ, Lee KS, Yim HJ, Tak WY, Hwang SG, Lee YJ, Lee CH, Kim DG, Kang YW, Kim YS; Korean Transient Elastography Study Group. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int. 2015;35:2246-2255. [PMID: 25682719 DOI: 10.1111/liv.12808] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
130 Hollinger FB, Lau DT. Hepatitis B: The Pathway to Recovery Through Treatment. Gastroenterology Clinics of North America 2006;35:895-931. [DOI: 10.1016/j.gtc.2006.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
131 Mateos ML, Tato M, Moreira V. [Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B]. Gastroenterol Hepatol 2006;29:71-3. [PMID: 16448607 DOI: 10.1157/13083902] [Reference Citation Analysis]
132 Perrillo R. Hepatitis B Virus Replication x Time Equals Trouble. Gastroenterology 2006;130:989-91. [DOI: 10.1053/j.gastro.2006.01.070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
133 Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4:599-608. [PMID: 15934864 DOI: 10.1517/14740338.4.3.599] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 6.2] [Reference Citation Analysis]
134 Moseley RH. Liver and biliary tract disorders: . Current Opinion in Gastroenterology 2005;21:257-9. [DOI: 10.1097/01.mog.0000159818.93779.fb] [Reference Citation Analysis]
135 Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27-33. [PMID: 19031469 DOI: 10.1002/jmv.21339] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 8.5] [Reference Citation Analysis]
136 Strauss E. Barriers to care of chronic hepatitis patients in Latin America. Arch Med Res. 2007;38:711-715. [PMID: 17613362 DOI: 10.1016/j.arcmed.2007.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
137 Buti M, Casado MA, Calleja JL, Salmeron J, Aguilar J, Rueda M, Esteban R. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2006;23:409-19. [DOI: 10.1111/j.1365-2036.2006.02767.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
138 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47:844-853. [PMID: 18302293 DOI: 10.1002/hep.22106] [Cited by in Crossref: 224] [Cited by in F6Publishing: 207] [Article Influence: 16.0] [Reference Citation Analysis]
140 Torres Salinas M. Hepatitis B en situaciones especiales. Gastroenterología y Hepatología 2006;29:76-81. [DOI: 10.1157/13097583] [Reference Citation Analysis]
141 Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M, Bhaumik P, Devarbhavi H, Dhiman RK, Dixit VK, Goel A, Goswami B, Kapoor D, Madan K, Narayan J, Nijhawan S, Pandey G, Rai RR, Sahu MK, Saraf N, Shalimar, Shenoy T, Thomas V, Wadhawan M; INASL Hepatitis B Taskforce. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. J Clin Exp Hepatol 2018;8:58-80. [PMID: 29743798 DOI: 10.1016/j.jceh.2017.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
142 Han A, Li L, Qing K, Qi X, Hou L, Luo X, Shi S, Ye F. Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). Bioorg Med Chem Lett 2013;23:1310-4. [PMID: 23369536 DOI: 10.1016/j.bmcl.2012.12.097] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
143 Ferreira MS, Borges AS. [Advances in the treatment of hepatitis B]. Rev Soc Bras Med Trop 2007;40:451-62. [PMID: 17876470 DOI: 10.1590/s0037-86822007000400016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
144 Hu KQ. A Practical Approach to Management of Chronic Hepatitis B. Int J Med Sci 2005;2:17-23. [PMID: 15968335 DOI: 10.7150/ijms.2.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
145 Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, Wei L, Wang GQ, Tanaka Y, Mizokami M. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541-548. [PMID: 17243057 DOI: 10.1086/511042] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
146 Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007;46:1769-1778. [PMID: 17929296 DOI: 10.1002/hep.21897] [Cited by in Crossref: 200] [Cited by in F6Publishing: 198] [Article Influence: 14.3] [Reference Citation Analysis]
147 Vlachos GD, Schulpis KH, Papakonstantinou E, Papadakis M, Elefsiniotis I, Papassotiriou I, Antsaklis A. Maternal chronic hepatitis B virus does not affect neonatal biotinidase activity. Acta Paediatr 2008;97:362-5. [PMID: 18241289 DOI: 10.1111/j.1651-2227.2007.00636.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob. 2005;4:13. [PMID: 16159399 DOI: 10.1186/1476-0711-4-13] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
149 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
150 Bravo-Grande JL, Asunción Blanco-González M, de la Torre-Robles JM, Asmat-Inostrosa MP, Fernández-Escribano M, Villalobos IM, Covadonga Caso-Pita M, Hervella-Ordoñez M, Cañibano Cimas LM, de la Fuente-Martín JM, Luisa Rodríguez de la Pinta M, Olivas JRB, Muñóz-Ruipérez C, Alonso López MA, Del Campo MT, Antonieta Ramírez Pérez M, Sánchez-Arcilla I, Marzola-Payares M, Rescalvo-Santiago F, Paula-Ortiz M, Sánchez-Santos JM, López-Pérez R. Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines. Vaccine 2021;39:554-63. [PMID: 33334613 DOI: 10.1016/j.vaccine.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528-536. [PMID: 16083710 DOI: 10.1053/j.gastro.2005.05.053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
152 Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center’s experience. Eur J Pediatr. 2007;166:195-199. [PMID: 16944240 DOI: 10.1007/s00431-006-0220-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
153 Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouillères O, Poupon R. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol. 2007;5:636-641. [PMID: 17428739 DOI: 10.1016/j.cgh.2007.01.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
154 Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn’s disease patient. Inflamm Bowel Dis. 2007;13:1450-1451. [PMID: 17712837 DOI: 10.1002/ibd.20202] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
155 Liu KZ, Hou W, Zumbika E, Ni Q. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Sci B. 2005;6:1182-1187. [PMID: 16358376 DOI: 10.1631/jzus.2005.B1182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
156 Zhang KY, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci 2007;98:1921-9. [PMID: 17888035 DOI: 10.1111/j.1349-7006.2007.00609.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
157 Narkhede YB, Gonzalez KJ, Strauch EM. Targeting Viral Surface Proteins through Structure-Based Design. Viruses 2021;13:1320. [PMID: 34372526 DOI: 10.3390/v13071320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Kalyoncu U, Emmungil H, Onat AM, Yılmaz S, Kaşifoglu T, Akar S, İnanç N, Yıldız F, Küçükşahin O, Karadağ Ö, Mercan R, Bes C, Yazısız V, Yılmazer B, Özmen M, Erten Ş, Şenel S, Yazıcı A, Taşçılar K, Kalfa M, Kiraz S, Kısacık B, Pehlivan Y, Kılıç L, Şimşek İ, Çefle A, Akkoç N, Direskeneli H, Erken E, Turgay M, Öztürk MA, Soy M, Aksu K, Dinç A, Ertenli İ. Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). Eur J Rheumatol 2015;2:149-54. [PMID: 27708953 DOI: 10.5152/eurjrheum.2015.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
159 Fung J, Cheung KS, Wong DK, Mak LY, To WP, Seto WK, Lai CL, Yuen MF. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology. 2018;68:462-472. [PMID: 29534307 DOI: 10.1002/hep.29874] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
160 Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005. [PMID: 19454492 DOI: 10.3324/haematol.2009.005819] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
161 Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11:965-991. [PMID: 17981237 DOI: 10.1016/j.cld.2007.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
162 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
163 Liu CJ, Kao JH, Chen PJ, Chen TC, Lin FY, Lai MY, Chen DS. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. J Viral Hepat 2006;13:387-95. [PMID: 16842441 DOI: 10.1111/j.1365-2893.2005.00704.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
164 Hardikar W, Schwarz KB. Treatment options for chronic hepatitis B and C infection in children. Expert Review of Anti-infective Therapy 2014;4:583-91. [DOI: 10.1586/14787210.4.4.583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Andreani T, Serfaty L, Poupon R, Chazouilleres O. Need to Strictly Define Hepatitis B Virus Immunotolerant Patients to Avoid Unnecessary Liver Biopsy. Gastroenterology 2008;135:2155-6. [DOI: 10.1053/j.gastro.2008.08.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
166 Robotin MC, Kansil MQ, George J, Howard K, Tipper S, Levy M, Phung N, Penman AG. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res 2010;10:215. [PMID: 20663140 DOI: 10.1186/1472-6963-10-215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
167 You H, Ma H, Liu T, Cong M, Wang P, Ou X, Wang X, Ren J, Li H, Wang B, Jia J. Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. J Viral Hepat 2009;16:876-82. [PMID: 19635048 DOI: 10.1111/j.1365-2893.2009.01145.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
168 Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. 2018;22:703-722. [PMID: 30266158 DOI: 10.1016/j.cld.2018.06.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
169 Tsai N. Diagnosis and management of chronic hepatitis B in the primary care setting. Postgrad Med 2006;119:28-36. [PMID: 16961050 DOI: 10.3810/pgm.2006.07.1745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
170 Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
171 Sherman M. Optimizing Management Strategies in Special Patient Populations. Am J Gastroenterology 2006;101:S26-31. [DOI: 10.1111/j.1572-0241.2006.00369.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
172 Truelove AL, Oleksyk TK, Shrestha S, Thio CL, Goedert JJ, Donfield SM, Kirk GD, Thomas DL, O'Brien SJ, Smith MW. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet 2008;35:255-64. [PMID: 18479293 DOI: 10.1111/j.1744-313X.2008.00770.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
173 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
174 Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol. 2006;21:1783-1788. [PMID: 17074014 DOI: 10.1111/j.1440-1746.2006.04567.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
175 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-165] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
176 Kerkar N. Hepatitis B in children: complexities in management. Pediatr Transplant 2005;9:685-91. [PMID: 16176431 DOI: 10.1111/j.1399-3046.2005.00393.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
177 Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-952. [PMID: 17021358 DOI: 10.1164/rccm.200510-1666st] [Cited by in Crossref: 597] [Cited by in F6Publishing: 220] [Article Influence: 37.3] [Reference Citation Analysis]
178 Kurihara T, Imazeki F, Yokosuka O, Fukai K, Kanda T, Kawai S, Saisho H. Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level. World J Gastroenterol 2005; 11(22): 3346-3350 [PMID: 15948237 DOI: 10.3748/wjg.v11.i22.3346] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
179 Weber B. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. Expert Rev Mol Diagn. 2005;5:75-91. [PMID: 15723594 DOI: 10.1586/14737159.5.1.75] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
180 Alizadeh AHM, Ranjbar M, Hajilooi M, Fallahian F. Association of promoter polymorphism of the CD14 C (-159) T endotoxin receptor gene with chronic hepatitis B. World J Gastroenterol 2006; 12(35): 5717-5720 [PMID: 17007028 DOI: 10.3748/wjg.v12.i35.5717] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
181 Yuen MF, Lai CL. Recommendations and potential future options in the treatment of hepatitis B. Expert Opin Pharmacother 2006;7:2225-31. [PMID: 17059379 DOI: 10.1517/14656566.7.16.2225] [Reference Citation Analysis]
182 Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J. 2009;6:163. [PMID: 19818142 DOI: 10.1186/1743-422x-6-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
183 Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66:1605-122; discussion 1605-122;. [PMID: 16956310 DOI: 10.2165/00003495-200666120-00009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
184 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-1651471-2334-11-165] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48-50. [PMID: 17368969 DOI: 10.1016/j.jcv.2007.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
186 Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther. 2008;30:317-323. [PMID: 18343270 DOI: 10.1016/j.clinthera.2008.02.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
187 Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment. Am J Hematol. 2008;83:673-675. [PMID: 18528824 DOI: 10.1002/ajh.21214] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
188 Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006;71:206-215. [PMID: 16716414 DOI: 10.1016/j.antiviral.2006.04.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
189 Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK. Cost-effectiveness of peginterferon α-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom: . European Journal of Gastroenterology & Hepatology 2007;19:631-8. [DOI: 10.1097/meg.0b013e3281108079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
190 D'Souza R, Foster GR. Diagnosis and treatment of chronic hepatitis B. J R Soc Med 2004;97:318-21. [PMID: 15229255 DOI: 10.1258/jrsm.97.7.318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
191 Aslan M, Nazlıgul Y, Aksoy N, Yılmaz N. A Case of Hyperthyroidy Developing in “Pegylated-Interferon” Therapy. Dig Dis Sci 2007;52:1194-6. [DOI: 10.1007/s10620-006-9318-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
192 Hui C, Lau GK. Clevudine for the treatment of chronic hepatitis B virus infection. Expert Opinion on Investigational Drugs 2005;14:1277-84. [DOI: 10.1517/13543784.14.10.1277] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
193 Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy. 2009;1:1053-1061. [PMID: 20635919 DOI: 10.2217/imt.09.59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
194 Li N, Ding H, Fan P, Lin X, Xu C, Wang W, Xu Z, Wang J. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasound Med Biol. 2010;36:1066-1075. [PMID: 20620694 DOI: 10.1016/j.ultrasmedbio.2010.04.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
195 Liu W, Zhu H, Wu W, He J, Chen Z. Inhibition effect produced by dominant negative mutant fusion protein PreS2-TLM-ScFv-HBcDN on HBV replication in vitro: Inhibition effect of hepatitis B virus replication in vitro. Journal of Viral Hepatitis 2012;19:295-300. [DOI: 10.1111/j.1365-2893.2011.01547.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
196 Santos SA, Uriel AJ, Park JS, Lucas J, Carriero D, Jaffe D, Dieterich DT. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen: . European Journal of Gastroenterology & Hepatology 2006;18:1247-53. [DOI: 10.1097/01.meg.0000243877.17444.5e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
197 Minuk GY, Cohen AJ, Assy N, Moser M. Viral hepatitis and the surgeon. HPB (Oxford) 2005;7:56-64. [PMID: 18333162 DOI: 10.1080/13651820410016633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
198 Song EY, Shin Y, Roh EY, Sue S, Park MH, Kim BH, Kim W, Yoon J, Lee Y, Park SJ, Jung EU, Lee J, Myung SJ, Kim Y, Lee H. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients. J Med Virol 2011;83:88-94. [DOI: 10.1002/jmv.21961] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
199 Zeng MD, Li YM, Chen CW, Lu LG, Fan JG, Wang BY, Mao YM. Guidelines for the diagnosis and treatment of alcoholic liver disease. J Dig Dis. 2008;9:113-116. [PMID: 18419646 DOI: 10.1111/j.1751-2980.2008.00332.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
200 Ting CT, Cheng YY, Tsai TH. Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats. Molecules 2017;22:E1034. [PMID: 28640225 DOI: 10.3390/molecules22071034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
201 Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Arakawa T, Fujimori M. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values: HCC in HBV Carriers With Normal ALT. J Med Virol 2010;82:539-45. [DOI: 10.1002/jmv.21686] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
202 Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 2007;46:1049-56. [DOI: 10.1002/hep.21783] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
203 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
204 Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology. 2008;48:1451-1459. [PMID: 18924246 DOI: 10.1002/hep.22518] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 6.4] [Reference Citation Analysis]
205 D'souza R, Foster GR. Diagnosis and Treatment of Chronic Hepatitis B. J R Soc Med 2004;97:318-21. [DOI: 10.1177/014107680409700703] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
206 Zhang XF, Wei T, Liu XM, Liu C, Lv Y. Impact of cigarette smoking on outcome of hepatocellular carcinoma after surgery in patients with hepatitis B. PLoS One. 2014;9:e85077. [PMID: 24454795 DOI: 10.1371/journal.pone.0085077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
207 Liaw Y. Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how? Hepatology 2007;45:266-8. [DOI: 10.1002/hep.21546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
208 Straley SD, Terrault NA. Chronic hepatitis B. Curr Treat Options Gastro 2004;7:477-89. [DOI: 10.1007/s11938-004-0007-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
209 Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 2008;15:434-441. [PMID: 18194171 DOI: 10.1111/j.1365-2893.2007.00957.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
210 Limquiaco JL, Wong J, Wong VW, Wong GL, Tse CH, Chan HY, Kwan KY, Lai PB, Chan HL. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol. 2009;81:224-229. [PMID: 19107976 DOI: 10.1002/jmv.21369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
211 Dumas L, Vergani D, Mieli-vergani G. Hepatitis B Virus: Something Old, Something New. Journal of Pediatric Gastroenterology & Nutrition 2007;44:14-7. [DOI: 10.1097/01.mpg.0000252189.20417.84] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
212 Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol. 2008;22:1031-1048. [PMID: 19187865 DOI: 10.1016/j.bpg.2008.11.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
213 Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005;22:519-528. [PMID: 16167968 DOI: 10.1111/j.1365-2036.2005.02616.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
214 Jung CW, Tan J, Tan N, Kuo MN, Ashok A, Eells SJ, Miller LG. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population. J Gastroenterol Hepatol. 2010;25:369-375. [PMID: 19929923 DOI: 10.1111/j.1440-1746.2009.06023.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
215 Zeng F, Xiang Y, Liang Z, Wang X, Huang D, Zhu S, Li M, Yang D, Wang D, Wang Y. Anti-Hepatitis B Virus Effects of Dehydrocheilanthifoline from Corydalis saxicola. Am J Chin Med 2013;41:119-30. [DOI: 10.1142/s0192415x13500092] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
216 Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol 2013;11:565-71. [PMID: 23333662 DOI: 10.1016/j.cgh.2012.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
217 Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 6252-6261 [PMID: 24876746 DOI: 10.3748/wjg.v20.i20.6252] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
218 Kwon HW, Lee HY, Kim SG, Kim W, Jung YJ, Kang KW, Chung JK, Lee MC, Lee DS. Quantitative measurement of serum hepatitis B surface antigen using an immunoradiometric assay in chronic hepatitis B. Nucl Med Mol Imaging 2011;45:15-20. [PMID: 24899973 DOI: 10.1007/s13139-010-0061-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Minami M, Okanoue T. Management of HBV infection in Japan. Hepatology Research 2007;37:S79-82. [DOI: 10.1111/j.1872-034x.2007.00109.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
220 Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Vegnente A, Little NR, Gardener SD, Jonas MM. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32. [DOI: 10.1002/hep.21020] [Cited by in Crossref: 107] [Cited by in F6Publishing: 78] [Article Influence: 6.7] [Reference Citation Analysis]
221 Fung J, Yuen MF, Yuen JC, Wong DK, Lai CL. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment Pharmacol Ther. 2007;26:377-382. [PMID: 17635372 DOI: 10.1111/j.1365-2036.2007.03390.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
222 Wong P, Fung T, Mak S, Lo K, Tong GM, Wong Y, Loo C, Lam EK, Wong AK. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005;20:1641-51. [DOI: 10.1111/j.1440-1746.2005.03837.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
223 Thomas HC. Hepatitis B and D. Medicine 2007;35:39-42. [DOI: 10.1053/j.mpmed.2006.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Perrillo RP. Therapy of hepatitis B — Viral suppression or eradication? Hepatology 2006;43:S182-93. [DOI: 10.1002/hep.20970] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
225 Forbi JC, Iperepolu OH, Zungwe T, Agwale SM. Prevalence of hepatitis B e antigen in chronic HBV carriers in North-central Nigeria. J Health Popul Nutr 2012;30:377-82. [PMID: 23304903 DOI: 10.3329/jhpn.v30i4.13289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
226 Lisker-melman M, Sayuk GS. Defining Optimal Therapeutic Outcomes in Chronic Hepatitis. Archives of Medical Research 2007;38:652-60. [DOI: 10.1016/j.arcmed.2006.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
227 Al-Qahtani AA, Al-Anazi MR, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khalaf NZ, Viswan NA, Al Ahdal MN. Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Liver Int. 2013; Oct 7. [Epub ahead of print]. [PMID: 24118788 DOI: 10.1111/liv.12347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
228 Masaadeh HA, Hayajneh WA, Alqudah EA. Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan. World J Gastroenterol 2008; 14(47): 7231-7234 [PMID: 19084939 DOI: 10.3748/wjg.14.7231] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
229 Zacharakis G, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, Archimandritis A, Papoutselis K. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005;77:173-9. [DOI: 10.1002/jmv.20434] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
230 Lakhani S, Davidson L, Priebat DA, Sherker AH. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2008;2:498-9. [PMID: 19669326 DOI: 10.1007/s12072-008-9099-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
231 Kessler HH. Comparison of currently available assays for detection of hepatitis B virus DNA in the routine diagnostic laboratory. Expert Review of Molecular Diagnostics 2014;5:531-6. [DOI: 10.1586/14737159.5.4.531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
232 Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445-1454. [PMID: 17409326 DOI: 10.1056/nejmra065142] [Cited by in Crossref: 195] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
233 Yuen M. Revisiting the natural history of chronic hepatitis B: Impact of new concepts on clinical management. J Gastroenterol Hepatol 2007;22:973-6. [DOI: 10.1111/j.1440-1746.2007.04938.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
234 Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877-883. [PMID: 21054683 DOI: 10.1111/j.1365-2893.2010.01386.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
235 Gültepe B, Dülger AC, Gültepe İ, Karadas S, Ebinç S, Esen R. Higher seroprevalence of hepatitis B virus antigen in patients with cystic hydatid disease than in patients referred to internal medicine clinics in Turkey. Korean J Parasitol 2014;52:47-9. [PMID: 24623881 DOI: 10.3347/kjp.2014.52.1.47] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
236 Lim CY, Kowdley KV. Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother. 2007;60:2-6. [PMID: 17483546 DOI: 10.1093/jac/dkm102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
237 Robins GW, Scott LJ, Keating GM. Peginterferon-??-2a (40kD): A Review of its Use in the Management of Patients with Chronic Hepatitis B. Drugs 2005;65:809-25. [DOI: 10.2165/00003495-200565060-00010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
238 Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006;50:2309-15. [PMID: 16801406 DOI: 10.1128/AAC.01313-05] [Cited by in Crossref: 31] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
239 Chen FP, Kung YY, Chen YC, Jong MS, Chen TJ, Chen FJ, Hwang SJ. Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in Taiwan. J Ethnopharmacol 2008;117:84-91. [PMID: 18321671 DOI: 10.1016/j.jep.2008.01.018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
240 Junaidi O, Di Bisceglie AM. Aging liver and hepatitis. Clin Geriatr Med 2007;23:889-903, viii. [PMID: 17923344 DOI: 10.1016/j.cger.2007.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
241 Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol. 2006;4:666-676. [PMID: 16765304 DOI: 10.1016/j.cgh.2006.03.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
242 Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-16. [PMID: 16799983 DOI: 10.1002/hep.21225] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
243 Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005;5:374-82. [PMID: 15919623 DOI: 10.1016/S1473-3099(05)70141-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
244 Vilar Gómez E, Grá Oramas B, Arús Soler E, Ruenes Domech C, Dávila González Y. [Sequential combination therapy with prednisone, lamivudine and interferon alfa-2b for HBeAg-positive chronic hepatitis B]. Gastroenterol Hepatol 2006;29:534-41. [PMID: 17129547 DOI: 10.1157/13094348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
245 Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, Yeon JE, Lee HS, Um SH, Byun KS. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat. 2011;18:287-293. [PMID: 20367793 DOI: 10.1111/j.1365-2893.2010.01304.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
246 Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. JCO 2012;30:3167-73. [DOI: 10.1200/jco.2011.40.7510] [Cited by in Crossref: 81] [Cited by in F6Publishing: 32] [Article Influence: 8.1] [Reference Citation Analysis]
247 Wong SN, Lok AS. Update on viral hepatitis: 2005. Curr Opin Gastroenterol 2006;22:241-7. [PMID: 16550038 DOI: 10.1097/01.mog.0000218960.48064.f2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
248 França P, Coelho H, Brandão C, Segadas J, Quintaes R, Carrilho F, Ono-nita S, Mattos A, Tovo C, Gouvea V, Sablon E, Vanderborght B. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation. Braz J Med Biol Res 2007;40:1605-14. [DOI: 10.1590/s0100-879x2006005000169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Silva LCD, Nova MLD, Ono-nita SK, Pinho JRR, Sitnik R, Santos VAD, Carrilho FJ. Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev Inst Med trop S Paulo 2009;51:261-8. [DOI: 10.1590/s0036-46652009000500005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
250 Perrillo R, Nair S. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2006. pp. 635-63. [DOI: 10.1016/b978-1-4160-3258-8.50036-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
251 Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol 2011; 3(12): 292-299 [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
252 Suzuki Y, Yotsuyanagi H, Okuse C, Nagase Y, Takahashi H, Moriya K, Suzuki M, Koike K, Iino S, Itoh F. Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: A case report. World J Gastroenterol 2007; 13(6): 964-969 [PMID: 17352033 DOI: 10.3748/wjg.v13.i6.964] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
253 Hwang JP, Hassan MM. Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer 2009;9:46. [PMID: 19193234 DOI: 10.1186/1471-2407-9-46] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
254 Cadranel JF, Lahmek P, Causse X, Bellaiche G, Bettan L, Fontanges T, Medini A, Henrion J, Chousterman M, Condat B. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis--results of a nationwide survey. Aliment Pharmacol Ther. 2007;26:565-576. [PMID: 17661760 DOI: 10.1111/j.1365-2036.2007.03400.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
255 Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs. 2007;16:777-786. [PMID: 17501691 DOI: 10.1517/13543784.16.6.777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
256 Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis. 2007;44:996-1000. [PMID: 17342656 DOI: 10.1086/512367] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
257 Xu WS, Zhao KK, Miao XH, Ni W, Cai X, Zhang RQ, Wang JX. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitroWorld J Gastroenterol 2010; 16(16): 2028-2037 [PMID: 20419842 DOI: 10.3748/wjg.v16.i16.2028] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
258 Farrell G, Fan J. Prevention of Hepatocellular Carcinoma. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 36-61. [DOI: 10.3109/9780203092880-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
259 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
260 Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47:428-434. [PMID: 18220290 DOI: 10.1002/hep.22065] [Cited by in Crossref: 172] [Cited by in F6Publishing: 158] [Article Influence: 12.3] [Reference Citation Analysis]
261 Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin Diagn Pathol 2006;23:132-48. [PMID: 17355087 DOI: 10.1053/j.semdp.2006.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
262 Fung SK, Fontana RJ. Management of Drug-Resistant Chronic Hepatitis B. Clinics in Liver Disease 2006;10:275-302. [DOI: 10.1016/j.cld.2006.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
263 Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006;36:100-13. [PMID: 16472264 DOI: 10.1111/j.1445-5994.2006.01027.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
264 Okushin H, Ohnishi T, Morii K, Uesaka K, Yuasa S. Short-term intravenous interferon therapy for chronic hepatitis B. World J Gastroenterol 2008; 14(19): 3038-3043 [PMID: 18494055 DOI: 10.3748/wjg.14.3038] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
265 Chao SD, Wang BM, Chang ET, Ma L, So SK. Medical training fails to prepare providers to care for patients with chronic hepatitis B infection. World J Gastroenterol 2015; 21(22): 6914-6923 [PMID: 26078568 DOI: 10.3748/wjg.v21.i22.6914] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
266 Marino D, Boso C, Crivellari G, Mazzarotto R, Stragliotto S, Farinati F, Aversa SM. Fatal HBV-Related Liver Failure during Lamivudine Therapy in a Patient with Non-Hodgkin's Lymphoma. Tumori 2008;94:748-9. [DOI: 10.1177/030089160809400519] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
267 Pérez-Rodríguez MT, Sopeña B, Crespo M, Rivera A, Blanco TGD, Ocampo A, Martínez-Vázquez C. Clinical significance of “anti-HBc alone” in human immunodeficiency virus-positive patients. World J Gastroenterol 2009; 15(10): 1237-1241 [PMID: 19291824 DOI: 10.3748/wjg.15.1237] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
268 Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100:616-623. [PMID: 15743360 DOI: 10.1111/j.1572-0241.2005.41289.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 8.2] [Reference Citation Analysis]
269 Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634-651. [PMID: 18715665 DOI: 10.1016/j.jhep.2008.07.013] [Cited by in Crossref: 225] [Cited by in F6Publishing: 218] [Article Influence: 16.1] [Reference Citation Analysis]
270 Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416-2420. [PMID: 19797507 DOI: 10.3899/jrheum.081324] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
271 Li KK, Liu Y, Yao PF, Chen Z, Wang H, Li J. Comparison of different genotyping methods for hepatitis B virus in a Chinese population. Shijie Huaren Xiaohua Zazhi 2014; 22(16): 2306-2316 [DOI: 10.11569/wcjd.v22.i16.2306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Santos Corraliza E, Fuertes Martín A. [Current knowledge on pathogeny, diagnosis and treatment of hepatitis B]. Med Clin (Barc) 2007;128:579-83. [PMID: 17462197 DOI: 10.1157/13101614] [Reference Citation Analysis]
273 ACT-HBV Asia Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26:47-58. [PMID: 18473475 DOI: 10.1111/j.1478-3231.2006.01374.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
274 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
275 Buti M. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:32-8. [PMID: 19100229 DOI: 10.1016/s0213-005x(08)76517-0] [Reference Citation Analysis]
276 Bawazir AA, Parry CM, Hart CA, Sallam TA, Beeching N, Cuevas LE. Seroepidemiology and risk factors of hepatitis B virus in Aden, Yemen. J Infect Public Health 2011;4:48-54. [PMID: 21338959 DOI: 10.1016/j.jiph.2010.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
277 Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34. [DOI: 10.1002/hep.23044] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
278 Kaplan DE, Medvedeva E, Serper M. Care quality and outcomes among US veterans with chronic hepatitis B in the hepatitis C direct-acting antiviral era. J Viral Hepat 2020;27:1082-92. [PMID: 32484991 DOI: 10.1111/jvh.13340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
279 Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005;25:1097-1107. [PMID: 16343058 DOI: 10.1111/j.1478-3231.2005.01177.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 4.4] [Reference Citation Analysis]
280 Gómez Rodríguez R, Guardiola Arévalo A, Gómez Moreno AZ, García Vela A, Gómez Hernando C, Rodríguez Merlo R, Sánchez Ruano JJ, de la Cruz Pérez G. [Characteristics of patients with chronic hepatitis B virus infection. analysis of a series of 474 patients]. Gastroenterol Hepatol 2013;36:243-53. [PMID: 23414836 DOI: 10.1016/j.gastrohep.2012.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
281 Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Garcia G, Ahmed A, Keeffe EB, Nguyen MH. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-70. [PMID: 22941429 DOI: 10.1097/MCG.0b013e31825ceed9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
282 Shinkai N, Tanaka Y, Ito K, Mukaide M, Hasegawa I, Asahina Y, Izumi N, Yatsuhashi H, Orito E, Joh T. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol. 2007;45:3191-3197. [PMID: 17652471 DOI: 10.1128/jcm.00411-07] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
283 Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Damavand B, Azimzadeh P, Derakhshan F, Sabahi F, Zali MR. Characterization of hepatitis B virus genome variability in Iranian patients with chronic infection, a nationwide study. J Med Virol 2012;84:414-23. [PMID: 22246826 DOI: 10.1002/jmv.23200] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
284 Sánchez-Quijano A, Lissen E. [Treatment of viral hepatitis (I). Treatment of chronic hepatitis B]. Enferm Infecc Microbiol Clin 2006;24:453-61; quiz 462. [PMID: 16956535 DOI: 10.1157/13091784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Wright TL, Avunduk C, Dienstag JL, Freston JW, Jacobson IM, Nord HJ, Sherman M. Advancing Patient Care: Integrating New Data. Am J Gastroenterology 2006;101:S32-9. [DOI: 10.1111/j.1572-0241.2006.00376.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
286 Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414-1419. [PMID: 16317671 DOI: 10.1002/hep.20939] [Cited by in Crossref: 202] [Cited by in F6Publishing: 184] [Article Influence: 11.9] [Reference Citation Analysis]
287 Chen XH, Pan QC, Tang ZH, Yu YS, Zang GQ. Protein transduction domain-hepatitis B virus core antigen fusion protein-induced specific cytotoxic T lymphocyte response inhibits hepatitis B virus replication in hepatitis B virus-transgenic mice. Shijie Huaren Xiaohua Zazhi 2009; 17(29): 2972-2977 [DOI: 10.11569/wcjd.v17.i29.2972] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, Zoulim F. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol. 2007;45:3948-3953. [PMID: 17942654 DOI: 10.1128/jcm.01180-07] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
289 Chen C, Iloeje UH, Yang H. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. Current Hepatitis Reports 2007;6:9-16. [DOI: 10.1007/bf02942173] [Cited by in Crossref: 12] [Article Influence: 0.8] [Reference Citation Analysis]
290 Heller S, Valencia-mayoral P. Treatment of Viral Hepatitis in Children. Archives of Medical Research 2007;38:702-10. [DOI: 10.1016/j.arcmed.2006.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
291 Opio CK, Lee WM, Kirkpatrick P. Entecavir. Nat Rev Drug Discov 2005;4:535-6. [DOI: 10.1038/nrd1780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
292 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. J Med Virol 2007;79:1286-92. [DOI: 10.1002/jmv.20928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
293 Chen MS Jr. Cancer health disparities among Asian Americans: what we do and what we need to do. Cancer. 2005;104:2895-2902. [PMID: 16270313 DOI: 10.1002/cncr.21501] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
294 Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049. [PMID: 16762627 DOI: 10.1053/j.gastro.2006.04.007] [Cited by in Crossref: 306] [Cited by in F6Publishing: 273] [Article Influence: 19.1] [Reference Citation Analysis]
295 Gerner P, Posselt HG, Krahl A, Ballauff A, Innerhofer A, Binder C, Wenzl TG, Zense M, Hector A, Dockter G, Adam R, Neubert J, Claßen M, Gemmern RV, Wirth S. Vitamin E treatment for children with chronic hepatitis B: A randomized placebo controlled trial. World J Gastroenterol 2008; 14(47): 7208-7213 [PMID: 19084935 DOI: 10.3748/wjg.14.7208] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
296 Hu P, Jiang J, Wang H, Pietropaolo K, Chao GC, Brown NA, Zhou X. Single-Dose and Multiple-Dose Pharmacokinetics and Safety of Telbivudine After Oral Administration in Healthy Chinese Subjects. The Journal of Clinical Pharmacology 2006;46:999-1007. [DOI: 10.1177/0091270006290623] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
297 Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol 2006;44:1390-9. [PMID: 16597867 DOI: 10.1128/JCM.44.4.1390-1399.2006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
298 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
299 Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. Journal of Hepatology 2007;47:608-17. [DOI: 10.1016/j.jhep.2007.07.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
300 Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620 [PMID: 24303089 DOI: 10.4254/wjh.v5.i11.612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
301 Wang CC, Liu CJ, Lai MY, Kao JH, Chen DS. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. Liver Int 2007;27:235-9. [PMID: 17311619 DOI: 10.1111/j.1478-3231.2006.01418.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
302 Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol. 2010;82:1850-1858. [PMID: 20872711 DOI: 10.1002/jmv.21902] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
303 Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat. 2011;18:377-383. [PMID: 21143343 DOI: 10.1111/j.1365-2893.2010.01401.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 113] [Article Influence: 9.4] [Reference Citation Analysis]
304 Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013;29:385-395. [PMID: 23768703 DOI: 10.1016/j.kjms.2012.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
305 Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149:3-13. [PMID: 20151975 DOI: 10.1111/j.1365-2141.2010.08076.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 96] [Article Influence: 7.7] [Reference Citation Analysis]
306 Hollinger FB, Lau DT. Hepatitis B: The Pathway to Recovery Through Treatment. Gastroenterology Clinics of North America 2006;35:425-61. [DOI: 10.1016/j.gtc.2006.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
307 Lim YS, Suh DJ. Current antiviral therapy for chronic hepatitis B. J Korean Med Sci. 2004;19:489-494. [PMID: 15308835 DOI: 10.3346/jkms.2004.19.4.489] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
308 Wang W, Shu Y, Bao H, Zhao W, Wang W, Wang Q, Lei X, Cui D, Yan Z. Genotypes and Hot Spot Mutations of Hepatitis B Virus in Northwest Chinese Population and Its Correlation with Diseases Progression. Biomed Res Int 2019;2019:3890962. [PMID: 31886206 DOI: 10.1155/2019/3890962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
309 Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag 2007;3:245-58. [PMID: 18360633 DOI: 10.2147/tcrm.2007.3.2.245] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
310 Almeida AM, da Silva AL, Cherchiglia ML, Andrade EI, de Oliveira GL, Acurcio Fde A. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine. Value Health. 2011;14:S24-S28. [PMID: 21839893 DOI: 10.1016/j.jval.2011.05.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
311 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.6] [Reference Citation Analysis]
312 Liu CJ, Chen PJ, Lai MY, Lin FY, Wang T, Kao JH, Chen DS. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int. 2006;26:949-955. [PMID: 16953835 DOI: 10.1111/j.1478-3231.2006.01319.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
313 Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350 [PMID: 16038032 DOI: 10.3748/wjg.v11.i28.4344] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
314 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(17): 1649-1653 [DOI: 10.11569/wcjd.v14.i17.1649] [Reference Citation Analysis]
315 Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003-1016. [PMID: 16984494 DOI: 10.1111/j.1365-2036.2006.03081.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
316 Robotin MC, George J, Supramaniam R, Sitas F, Penman AG. Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Medical Journal of Australia 2008;188:363-5. [DOI: 10.5694/j.1326-5377.2008.tb01656.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
317 Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Clin Mol Hepatol 2020;26:352-63. [PMID: 32460460 DOI: 10.3350/cmh.2019.0044n] [Reference Citation Analysis]
318 Amin P, Amin V. Viral Sepsis. In: Vincent J, editor. Annual Update in Intensive Care and Emergency Medicine 2015. Cham: Springer International Publishing; 2015. pp. 37-59. [DOI: 10.1007/978-3-319-13761-2_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
319 Khadem-Ansari MH, Omrani MD, Rasmi Y, Ghavam A. Diagnostic validity of the chemiluminescent method compared to polymerase chain reaction for hepatitis B virus detection in the routine clinical diagnostic laboratory. Adv Biomed Res. 2014;3:116. [PMID: 24949287 DOI: 10.4103/2277-9175.133178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
320 Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2006;23:99-106. [PMID: 16393286 DOI: 10.1111/j.1365-2036.2006.02731.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
321 Sobhonslidsuk A, Ungkanont A. A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor. World J Gastroenterol 2007; 13(7): 1138-1140 [PMID: 17373754 DOI: 10.3748/wjg.v13.i7.1138] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
322 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1212] [Cited by in F6Publishing: 538] [Article Influence: 86.6] [Reference Citation Analysis]
323 Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10:2399-2406. [PMID: 19761353 DOI: 10.1517/14656560903251710] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
324 Li YM, Fan JG, Wang BY, Lu LG, Shi JP, Niu JQ, Shen W; Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of alcoholic liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 167-170). J Dig Dis. 2011;12:45-50. [PMID: 21276208 DOI: 10.1111/j.1751-2980.2010.00477.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
325 Hwang S, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, Moon DB, Ha TY, Lim YS, Jung DH. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl. 2006;12:993-997. [PMID: 16721765 DOI: 10.1002/lt.20799] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
326 Yu SK, Kwon OS, Jung HS, Bae KS, Kwon KA, Kim YK, Kim YS, Kim JH. Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. J Korean Med Sci. 2010;25:564-569. [PMID: 20357999 DOI: 10.3346/jkms.2010.25.4.564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
327 Dai C, Chuang W, Jen Hou N, Lee L, Hsieh M, Lin Z, Chen S, Huang J, Hsieh M, Wang L, Tsai J, Wen-yu, Yu M. Early mortality in taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. Clinical Therapeutics 2006;28:2081-92. [DOI: 10.1016/j.clinthera.2006.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]